Previous close | 1.3000 |
Open | 1.3400 |
Bid | 1.3600 x 1000 |
Ask | 1.3900 x 800 |
Day's range | 1.3200 - 1.4200 |
52-week range | 0.7800 - 2.4800 |
Volume | |
Avg. volume | 4,982,686 |
Market cap | 287.145M |
Beta (5Y monthly) | 0.84 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
With the business potentially at an important milestone, we thought we'd take a closer look at Akebia Therapeutics...
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries. The approval of Vafseo is based on e
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.